Wedbush Reiterates Outperform on Keros Therapeutics, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Keros Therapeutics (NASDAQ:KROS) and maintained a price target of $86.
November 13, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst reaffirms Outperform rating on Keros Therapeutics with a maintained price target of $86, indicating a positive outlook on the stock.
The reiteration of an Outperform rating by a reputable analyst like Andreas Argyrides from Wedbush is a strong positive signal for investors, suggesting confidence in the company's future performance. The maintained price target of $86 implies a significant upside potential from the current trading price, which could lead to increased investor interest and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100